The Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaLuAtion (UMBRELLA): objectives, design, and baseline results

• Published in: Breast cancer research and treatment 2017-07, Vol.164 (2), p.445-450
• Main Authors: Young-Afat, D. A., van Gils, C. H., van den Bongard, H. J. G. D., Verkooijen, H. M.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Anxiety; Breast cancer; Breast Neoplasms - psychology; Cancer research; Epidemiology; Exercise; Fatigue; Female; Health risk assessment; Humans; Intervention; Medicine; Medicine & Public Health; Mental depression; Middle Aged; Observational Studies as Topic; Oncology; Patient Reported Outcome Measures; Physical activity; Physical fitness; Prospective Studies; Quality of life; Quality of Life - psychology; Randomized Controlled Trials as Topic; Research Design; Studies
• ISSN: 0167-6806; 1573-7217
• DOI: 10.1007/s10549-017-4242-4

Purpose In oncology, RCTs are often beset by slow recruitment, limited generalizability, and strong preferences for interventions by patients and physicians. The cohort multiple randomized controlled trial (cmRCT) is an innovative design with the potential to overcome those challenges. In cmRCT, a prospective cohort serves as an infrastructure for multiple RCTs. We implemented cmRCT in a clinical breast cancer setting by creating UMBRELLA—a large prospective cohort of breast cancer and DCIS patients/survivors. Methods For all participants, clinical data and patient-reported outcomes (PROs, i.e., quality of life, fatigue, anxiety and depression, physical activity, work ability, and cosmetic satisfaction) are being collected at regular time-intervals for a period of 10 years. These data are being used both for observational and randomized studies. For each intervention to be tested against standard care, a subcohort of eligible patients is identified within UMBRELLA. From this subcohort, a random sample of patients is offered the intervention. Their outcomes are compared to the outcomes of patients receiving standard care. Results So far, between October 2013 and July 2016, we have recruited 1308 participants. In this period, 1308/1486 (88%) patients who were invited for participation in UMBRELLA consented to cohort participation. Of these patients, 1138 (87%) gave broad consent for randomization to future interventions. Return rate for PROs at baseline were 80%, and varied from 67 to 74% during follow-up. Several observational studies—and the first randomized intervention study—are currently ongoing. Conclusions Results from UMBRELLA show that this novel study design is feasible and acceptable to patients in a clinical breast cancer setting. We invite researchers who are interested in conducting randomized or observational studies within the UMBRELLA cohort to contact the UMBRELLA scientific advisory board.